abdavomeran

N/A

Report date: 2026/05/13 09:17:25

Base Information

Drug Nameabdavomeran
Drug Alias NameBNT162b1
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulantsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsRNA Virus Infections +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth AfricaGermany +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBiontech Se
China Registration ClassN/A

Develop Information

Active CompaniesBiontech Se
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsRNA Virus Infections +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A